ProQR Therapeutics N.V.
- Open
- 2.26
- Day high
- 2.29
- Day low
- 2.12
- Prev close
- 2.29
- Volume
- 944K
- Mkt cap
- $301M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.3
- P/S
- 14.0
- Yield
- —
- Per share
- —
- ▲Insiders net buying $1.3M over the last 3 months (5 open-market buys, 0 sales)
- 🏛Institutions reducing (13F)
ProQR Therapeutics N.V. (PRQR) is a Healthcare company listed on NASDAQ. The stock is down 5% over the past year. Over the trailing 3 months, insiders filed 5 open-market buys and 0 sales (SEC Form 4).
ProQR Therapeutics N.V. (PRQR) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 4 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
PRQR earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 13, 2026 | $-0.13 | $-0.10 | +23.2% | $10M | +122.0% |
| May 12, 2026 | $-0.15 | $-0.15 | +0.0% | $2M | -54.4% |
| Mar 12, 2026 | $-0.10 | $-0.09 | +13.8% | $5M | -13.8% |
| Nov 6, 2025 | $-0.10 | $-0.12 | -20.0% | $3M | -44.2% |
| Aug 7, 2025 | $-0.08 | $-0.14 | -75.0% | $4M | -18.2% |
| May 8, 2025 | $-0.09 | $-0.11 | -22.2% | $5M | +3.1% |
| Mar 13, 2025 | $-0.10 | $-0.10 | +0.0% | $4M | -18.1% |
| Nov 7, 2024 | $-0.12 | $-0.11 | +8.3% | $4M | -39.8% |
| Aug 8, 2024 | $-0.12 | $-0.03 | +75.0% | $7M | -43.4% |
| May 9, 2024 | $-0.12 | $-0.10 | +16.7% | $5M | +70.5% |
| Mar 13, 2024 | $-0.08 | $-0.08 | +0.0% | $4M | -79.8% |
| Aug 3, 2023 | $-0.12 | $-0.11 | +8.3% | $1M | -23.1% |
PRQR insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 3, 2026 | de Boer Daniel Antondirector, officer: Chief Executive Officer | Buy | 200,000 | $1.77 |
| Jul 21, 2026 | Filius Bartdirector | Buy | 150,000 | $1.72 |
| Jul 13, 2026 | de Boer Daniel Antondirector, officer: Chief Executive Officer | Buy | 150,000 | $1.74 |
| Jul 8, 2026 | de Boer Daniel Antondirector, officer: Chief Executive Officer | Buy | 150,000 | $1.59 |
| Jun 30, 2026 | Hinsch Gylvin Lykkedirector | Grant | 14,595 | $1.42 |
| Jun 30, 2026 | Filius Bartdirector | Buy | 150,000 | $1.54 |
Source: PRQR SEC Form 4 filings, latest Aug 3, 2026. For informational purposes only — not investment advice.
See the full PRQR insider & 13F page →ProQR Therapeutics N.V. company profile
Overview
ProQR Therapeutics N.V. (NASDAQ:PRQR) is a Dutch biopharmaceutical company founded in 2012 and headquartered in Leiden, the Netherlands. The company went public in September 2014 and specializes in developing RNA-based therapeutic treatments for rare genetic disorders. ProQR focuses primarily on inherited diseases that cause blindness and other serious genetic conditions, utilizing innovative RNA editing and antisense oligonucleotide technologies to address previously untreatable genetic mutations.
Business
ProQR operates in the biotechnology sector, specifically focusing on RNA-based therapeutics for rare genetic diseases. The company's core business revolves around developing treatments that can modify or correct faulty genetic instructions at the RNA level, rather than attempting to alter DNA directly. The company's primary therapeutic approach uses antisense oligonucleotides (ASOs), which are short DNA-like molecules designed to bind to specific RNA sequences and modify how genes are expressed. This technology allows ProQR to potentially treat genetic diseases by either blocking harmful protein production or restoring the production of beneficial proteins that are missing due to genetic mutations. ProQR's lead product candidates include sepofarsen, currently in Phase II/III clinical trials for treating Leber Congenital Amaurosis 10 (LCA10), a rare inherited eye disease that causes severe vision loss or blindness from birth. The company is also developing ultevursen for USH2A-mediated retinitis pigmentosa and Usher syndrome, conditions that cause progressive vision and hearing loss. Additionally, ProQR is advancing its proprietary Axiomer RNA base-editing platform, a next-generation technology that can make precise edits to RNA without permanently altering the underlying DNA. This platform represents a potentially broader approach to treating genetic diseases beyond the company's current antisense oligonucleotide programs. The company generates revenue primarily through research collaborations and licensing agreements, including partnerships with major pharmaceutical companies like Eli Lilly for developing treatments targeting genetic disorders in the liver and nervous system.
Competitive moat
ProQR's competitive moat is relatively narrow but defensible within its specialized niche of RNA-based therapeutics for rare genetic diseases. The company's primary competitive advantages stem from its specialized expertise in antisense oligonucleotide design and its proprietary Axiomer RNA base-editing platform, which represents several years of research and development investment that would be difficult for competitors to quickly replicate. The company benefits from first-mover advantages in specific rare disease indications, particularly in inherited retinal diseases where it has established clinical trial infrastructure and regulatory relationships. ProQR's deep understanding of the complex RNA biology involved in these conditions creates some technical barriers to entry for new competitors. However, the company's moat faces significant challenges. Large pharmaceutical companies with substantially greater resources are increasingly investing in RNA therapeutics, potentially developing competing treatments with faster timelines and larger clinical trial capabilities. Companies like Roche, Novartis, and other major players have entered the ophthalmology space with significant R&D budgets that dwarf ProQR's resources. The regulatory pathway for rare disease treatments provides some protection through orphan drug designations and market exclusivity periods, but these advantages are temporary and depend on successful clinical outcomes. Additionally, gene therapy approaches from companies like Luxturna (Spark Therapeutics) represent alternative treatment modalities that could potentially address the same patient populations with different technological approaches. ProQR's moat is further constrained by its dependence on clinical trial success, as failure in key trials could quickly erode competitive positioning. The company's limited financial resources compared to larger competitors also restrict its ability to pursue multiple simultaneous development programs, concentrating risk in a smaller number of assets.
Risks & safety
ProQR presents a moderate margin of safety profile typical of clinical-stage biotechnology companies, with adequate liquidity but ongoing cash burn concerns. • Cash position: $145 million in cash and short-term investments as of Q1 2025, providing approximately 2-3 years of runway at current burn rates • Cash burn: Operating cash flow negative $39.5 million in 2024, with quarterly burn rates of approximately $10-17 million • Debt levels: Low debt-to-equity ratio of 0.21, indicating minimal solvency risk from debt obligations • Current ratio: Strong liquidity position with current ratio of 4.1, indicating ability to meet short-term obligations • Valuation metrics: Trading at negative P/E ratios due to losses, but enterprise value to EBITDA of -0.34x suggests potential undervaluation • Graham net-net: 0.59, indicating the stock trades below liquidation value of current assets • Additional considerations: Clinical trial binary risk events could dramatically impact valuation; partnership with Eli Lilly provides some validation and potential milestone payments; limited revenue diversification creates concentration risk
Recent development
Based on available financial data, ProQR has been advancing its clinical pipeline while managing cash resources carefully. The company's lead program sepofarsen has progressed into Phase II/III trials for LCA10, representing a significant milestone in the company's development trajectory. This advancement into late-stage trials demonstrates regulatory confidence in the therapy's potential and brings the company closer to potential commercialization. ProQR has strengthened its financial position through strategic partnerships, most notably with Eli Lilly and Company for discovering and developing treatments for genetic disorders affecting the liver and nervous system. This collaboration provides both validation of ProQR's technology platform and a source of research funding and milestone payments that help extend the company's cash runway. The company has been developing its Axiomer RNA base-editing platform as a next-generation technology that could expand its addressable market beyond current antisense oligonucleotide programs. This platform development represents a strategic pivot toward more versatile RNA editing capabilities that could potentially address a broader range of genetic diseases. ProQR has also been optimizing its clinical trial operations and focusing resources on its highest-priority programs while maintaining financial discipline. The company's cash burn has remained relatively stable, suggesting effective cost management while advancing key clinical programs.
PRQR company profile · for informational purposes only — not investment advice.
Track PRQR with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free